Trial · NCT07567378
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
NCT07567378, Not yet recruiting, JULIO GRANADOS MONTIEL
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry. Trials, record NCT07567378. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07567378
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
- NCT number
- NCT07567378
- Status
- Not yet recruiting
- Enrollment
- 30 participants, estimated
- Lead sponsor
- JULIO GRANADOS MONTIEL
- Conditions
Psoriatic Arthritis, Osteoarthitis, Knee, Diabetes (DM), Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder), Insulin Resistance Syndrome, Metabolic Syndrome, Heart Failure, Preserved Ejection Fraction, Coronary Artery Disease, Atrial Fibrillation (AF), Non Alcholic Fatty Liver Disease, Sarcopenia, Pericardium
- Interventions
- Tirzepatide
- First posted
- 2026-05-05
- Last updated
- 2026-05-12
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ACR20 response rate at Week 4 in the Mechanistic Analysis Set | week 4 | Proportion of patients in the Mechanistic Analysis Set (tirzepatide exposure ≤16 weeks at Week 0 and delta-BMI \<1.0 kg/m² through Week 4) achieving ACR20 response (American College of Rheumatology 20% improvement criteria) at Week 4, assessed by standardized clinical evaluation. |
| Primary | Proportion of Week-4 ACR20 response mediated by biomarker panel in the Mechanistic Analysis Set | Week 4 | Proportion of the Week-4 ACR20 response mediated by the combined biomarker panel (high-sensitivity C-reactive protein, SERPINB2, dipeptidyl peptidase-4 activity) in the Mechanistic Analysis Set, assessed by the MacKinnon product-of-coefficients method with 10,000 bias-corrected and accelerated (BCa) bootstrap iterations. Decision thresholds are prespecified in the Statistical Analysis Plan. |
| Secondary | Change in knee cartilage T2 relaxation time from Week 0 to Week 52 | Week 0 and week 52 | Change in femoro-tibial and patellar cartilage T2 relaxation time from Week 0 to Week 52, bilateral knees, stratified by zone (medial femur, lateral femur, medial tibia, lateral tibia, patella), analyzed at Ci3M UAM-Iztapalapa on Philips 3T platform. Primary analysis: linear mixed-effects model with random intercepts for patient and for knee-within-patient. |
| Secondary | Change in epicardial adipose tissue volume from Week 0 to Week 52 | week 0 and week 52 | Change in epicardial adipose tissue (EAT) volume from Week 0 to Week 52 by non-contrast cardiac CT with prospective ECG gating at the Instituto Nacional de Cardiología Ignacio Chávez. Primary analysis: linear mixed-effects model adjusted for baseline EAT volume, age, sex, and baseline BMI. Unit of Measure: milliliters (mL) |
| Secondary | Change in epicardial adipose tissue mean attenuation from Week 0 to Week 52 | week 0 and week 52 | Change in epicardial adipose tissue (EAT) mean attenuation from Week 0 to Week 52 on the same non-contrast cardiac CT acquisitions at the Instituto Nacional de Cardiología Ignacio Chávez. Primary analysis: linear mixed-effects model adjusted for baseline EAT mean attenuation, age, sex, and baseline BMI. Units of Measure: Hounsfield units (HU) |
| Secondary | Change in epicardial adipose tissue radiomic texture composite z-score from Week 0 to Week 52 | week 0 and week 52 | Change in a prespecified compact radiomic signature derived from up to five IBSI-standardized texture features (first-order, GLCM, GLRLM, GLSZM, NGTDM families) computed on non-contrast cardiac CT EAT segmentations and expressed as a normalized composite z-score, from Week 0 to Week 52. Primary analysis: linear mixed-effects model adjusted for baseline composite z-score, age, sex, and baseline BMI. Units of Measure: z-score (dimensionless) |
| Secondary | Longitudinal visceral adipose tissue trajectory over six timepoints | week 0 through week 52 | Visceral adipose tissue (VAT) volume by seca multi-frequency bioelectrical impedance analysis at Week 0, 2, 4, 12, 24, and 52 at Universidad La Salle México. Trajectory analyzed by linear mixed-effects model with random intercepts and slopes per patient. |
| Secondary | Longitudinal phase-angle trajectory (aging biomarker) over six timepoints | week 0 through week 52 | Bioimpedance phase angle (an established aging-biology biomarker) measured by seca mBCA at the six longitudinal timepoints. Trajectory and slope modeled per patient and stratified by baseline age tercile. |
| Secondary | HLA-stratified articular and cardiac response | week 4 and week 52 | ACR20 response at Week 4 and EAT radiomic change at Week 52 stratified by HLA Class I and Class II allele-group profile (INCMNSZ Transplant Department PCR-SSO Reverse Luminex typing). Hypothesis-generating. |
| Secondary | Change in Leeds Enthesitis Index (LEI) from Week 0 to Week 52 in the psoriatic arthritis subgroup | week 0 and week 52 | Change in LEI score (range 0-6, one point per tender enthesis at six prespecified entheseal sites) from Week 0 to Week 52 in the subgroup with CASPAR-positive psoriatic arthritis. Higher score indicates greater number of tender entheses. Primary analysis: paired t-test or Wilcoxon signed-rank within subgroup. Unit of Measure: score on a 0-6 scale (LEI) |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07567378
GET https://conductscience.org/api/trials/v1/NCT07567378/registered